Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy
Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy
复制标题
DOI：
10.1054/bjoc.1999.0881
复制
发表时间：
2000-01-01
影响因子：
8.8
通讯作者：
Kotz, R
中科院分区：
文献类型：
--
作者：
Trieb, K;Gerth, R;Kotz, R
热休克蛋白90（Hsp 90）的自身抗体已被报道为乳腺癌患者的预后标志物。从20个高级别骨肉瘤患者的血清进行了测试，在诊断时，通过酶联免疫吸附试验。抗Hsp90抗体的存在与对新辅助化疗的更好反应相关（P < 0.01），而抗Hsp90抗体的缺乏与转移的发展相关。这些数据表明，抗Hsp90抗体可能是人类骨肉瘤的预测价值。(C)2000年癌症研究运动。
Autoantibodies to the heat shock protein 90 (Hsp 90) have been reported as prognostic marker in breast cancer patients. Sera from 20 high-grade osteosarcoma patients were tested at the time of diagnosis by enzyme-linked immunosorbent assay. Presence of anti-Hsp90 antibodies correlated with a better response to neoadjuvant chemotherapy (P < 0.01), whereas the absence correlated with development of metastases. These data suggest that anti-Hsp90 antibodies might be of predictive value in human osteosarcoma. (C) 2000 Cancer Research Campaign.